Analysis of 20 years of data highlights differences in reimbursement trends across ophthalmology subspecialties and practice ...

Ocugen has announced positive preliminary 12-month data from its phase 2 ArMaDa trial evaluating OCU410 (AAV5-RORA) for the ...

Panelists discuss how emerging therapies—including TKIs, sustained-release implants, and gene therapy—may reduce treatment ...

Hemodialysis significantly alters anterior and posterior eye segments, affecting parameters like anterior chamber depth, lens ...

Ocugen has announced the publication of positive results from its phase 1 GARDian1 trial of OCU410ST, a gene therapy for ...

EDOF technology, previously used in intraocular lenses, is now available in contact lenses, offering significant improvements ...

“The non-invasive in vivo optical imaging of rhodopsin activation extends the diagnostic capability of ORG and may facilitate ...

The US Food and Drug Administration (FDA) has granted Fast Track Designation to Complement Therapeutics’ CTx001, the ...

An editorial published in the New England Journal of Medicine 1 referred to the Photovoltaic Retina Implant Microarray (PRIMA ...

Ollin Biosciences has announced positive topline results from its randomized, head-to-head Phase 1b JADE clinical study ...

Rayner's Sophi Phacoemulsification System, cleared by the FDA, is now available to US cataract surgeons, enhancing surgical ...

The US Food and Drug Administration has granted breakthrough therapy designation to Oculis’ neuroprotective candidate ...